Adam C. Winters
A5037817373- Inflammatory Bowel Disease
- Microscopic Colitis
- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Eosinophilic Esophagitis
- Alcohol Consumption and Health Effects
- Hepatocellular Carcinoma Treatment and Prognosis
- Organ Transplantation Techniques and Outcomes
- Pregnancy and Medication Impact
- Substance Abuse Treatment and Outcomes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Liver Diseases and Immunity
- Global Health Workforce Issues
- Cancer Immunotherapy and Biomarkers
- Health Systems, Economic Evaluations, Quality of Life
- Diversity and Career in Medicine
- Iron Metabolism and Disorders
- Respiratory Support and Mechanisms
- Eosinophilic Disorders and Syndromes
- Hepatitis C virus research
- Hemoglobinopathies and Related Disorders
- Primary Care and Health Outcomes
- Sodium Intake and Health
- Academic Publishing and Open Access
University of South Florida
2025
Icahn School of Medicine at Mount Sinai
2017-2024
University of California, Los Angeles
2019-2021
NYU Langone Health
2020
Robert Bosch (Germany)
2019
Mount Sinai Medical Center
2018
Jefferson College
2015
Thomas Jefferson University
2012
University of Maryland, Baltimore
2004
University of Maryland, College Park
2004
We aimed to quantify the safety and effectiveness of vedolizumab (VDZ) when used for UC, identify predictors response treatment.Retrospective review (May 2014-December 2016) VICTORY Consortium data. Adults with follow-up after starting VDZ clinically active UC were included. Primary outcomes cumulative rates clinical remission (resolution all UC-related symptoms) endoscopic (Mayo sub-score 0). Key secondary included corticosteroid-free deep (clinical remission). Cox proportional hazard...
As more treatment options for inflammatory bowel diseases become available, it is important to identify patients most likely respond different therapies. We created and validated a scoring system with Crohn's disease (CD) who vedolizumab.
There are few real-world data on the safety of vedolizumab for treatment Crohn's disease (CD) or ulcerative colitis (UC). We quantified rates and identified factors significantly associated with infectious non-infectious adverse events in clinical practice.We performed a retrospective review from multicenter consortium database (from May 2014 through June 2017). Infectious were defined as those requiring antibiotics, hospitalization, discontinuation, resulting death. Rates proportions per...
Background & AimsWe created and validated a clinical decision support tool (CDST) to predict outcomes of vedolizumab therapy for ulcerative colitis (UC).MethodsWe performed logistic regression analyses data from the GEMINI 1 trial, 620 patients with UC who received induction maintenance (derivation cohort), identify factors associated corticosteroid-free remission (full Mayo score 2 or less, no subscore above 1). We used these develop model treatment, which we called CDST. evaluated...
Background & AimsPatients with Crohn's disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates response to tumor necrosis factor (TNF) antagonists than patients longer duration. Little is known about the association between and other biologic agents. We aimed evaluate CD or UC vedolizumab, stratified by duration.MethodsWe analyzed data from a retrospective, multicenter, consortium (n = 650) 437) treated vedolizumab May 2014 through December 2016. Using time event...
We aimed to compare safety and effectiveness of vedolizumab tumor necrosis factor (TNF)-antagonist therapy in ulcerative colitis routine practice.A multicenter, retrospective, observational cohort study (May 2014 December 2017) patients treated with or TNF-antagonist therapy. Propensity score weighted comparisons for development serious adverse events achievement clinical remission, steroid-free deep remission. A priori determined subgroup TNF-antagonist-naïve -exposed patients, against...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by the buildup of amyloid-β and tau protein tangles. Alcohol use has been identified as risk factor for AD; however, molecular mechanisms underlying this potential causal link remain elusive. An emerging area research focuses on role microglia, brain's innate immune cells, in AD pathogenesis, with evidence suggesting that alcohol exposure may prime microglia to exhibit an exaggerated response when they are...
Liver transplantation (LT) is the only curative treatment for end-stage liver disease and significantly improves patient outcomes. However, LT resource-intensive costly, with expenditures rising dramatically in recent years. Factors contributing to this increase cost include expanded transplant criteria, utilization of marginal organs, broader organ distribution, resulting significant logistical expenses. Advanced technologies like perfusion devices, while promising better outcomes, further...
Abstract Background Vedolizumab effectiveness estimates immediately after Food and Drug Administration (FDA) approval for ulcerative colitis (UC) Crohn’s disease (CD) are limited by use in refractory populations. We aimed to compare treatment patterns outcomes of vedolizumab 2 time frames FDA approval. Methods used data sets trend analysis, an academic multicenter consortium (VICTORY) the Truven MarketScan database, periods, May 2014–June 2015 (Era 1) July 2015–June 2017 2). VICTORY...
We aimed to compare the effectiveness of vedolizumab (VDZ) tumour necrosis factor (TNF)-antagonist therapy for Crohn’s disease (CD). Using a multicentre, US-based consortium CD patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting age, sex, prior CD-related hospitalisation within previous year, stricturing penetrating complication history, bowel surgery, severity, steroid refractoriness dependence, and failure. Treatment response was...
Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death worldwide. Society guidelines recommend surveillance with abdominal ultrasound or without serum alpha‐fetoprotein every 6 months for adults at increased risk developing HCC. However, adherence often suboptimal. We assessed the feasibility coordinated telephone outreach program unscreened patients cirrhosis within Veteran’s Affairs (VA) health care system. Using patient dashboard advanced chronic liver disease in VA...
We aimed to compare the effectiveness of vedolizumab (VDZ) tumour necrosis factor (TNF)-antagonist therapy for ulcerative colitis (UC). Using a multicentre, US-based consortium UC patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting age, sex, prior UC-related hospitalisation within previous year, disease extent, severity, steroid refractoriness dependence, and failure. Treatment response was categorised using physician global...
We compared the safety profile of vedolizumab (VDZ) to tumour necrosis factor (TNF)-antagonist therapy for Crohn's disease (CD) and ulcerative colitis (UC). Using a multicentre US-based consortium CD UC patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting age, sex, prior disease-related hospitalisation within previous year, phenotype (stricturing penetrating complication history CD, extent UC), severity, bowel surgery steroid...
Ruxolitinib is increasingly being utilized for the treatment of myelofibrosis and polycythemia vera, but potential hepatic toxicity poorly understood. We performed a retrospective review damage occurring in patients with myeloproliferative neoplasms receiving ruxolitinib. Relevant histologic images liver biopsies were reviewed by an experienced pathologist reported to multidisciplinary team including hepatology hematology. A variety pathology was observed extramedullary hematopoiesis,...
End-stage liver disease (ESLD) is an increasingly prevalent condition with high morbidity and mortality, especially for those ineligible transplantation. Patients ESLD, along their family caregivers, have significant needs related to quality of life, there increasing attention being paid integration palliative care (PC) principles into routine throughout the spectrum. To provide upstream these patients it essential PC providers understand complex psychosocial physical be aware unique...